The Facilitated Access to Screening Technology (FAST) lab at Novartis provides a mechanism to collaborate with academic institutes who are interested in screening a part of the Novartis compound deck available for public use against new targets or testing an assay technology within an industrial setting. The Novartis Institutes of Tropical Diseases (NITD) has utilized the FAST lab to collaborate with academic labs who have novel targets in Leishmania, Schistosomiasis, and Chagas disease as well as SARS-CoV-2. This presentation will illustrate the FAST lab model and the resources available and provide example NITD collaborations employing biochemical assays for targets in infectious diseases.